|
| Wednesday, 28 July 2010, 10:00 HKT/SGT | |
| |  | |
Source: A*STAR | |
|
|
|
SINGAPORE, July 28, 2010 - (ACN Newswire) - MediPurpose(R), a Singapore-based medical device innovation and medical product distribution company, today announced the launch of its latest safety medical product, the babyLance(TM) heel incision device for infants, in North America and Europe. The babyLance heel incision device provides better control in drawing blood from newborn infants for various tests, removing the need for conventional needle-pricking of fingers.
 | | MediPurpose Launches New babyLance(TM) Infant Heel Incision Device Invented by A*STAR Research Scientist |
Designed and invented by Mr Sun Jian Ping, a research scientist seconded from the Singapore Institute of Manufacturing Technology (SIMTech), a research institute of the Agency for Science, Technology and Research, (A*STAR), the babyLance heel incision device, uses an innovative activation mechanism to improve the incision performance. It reduces the penetration depth thus avoiding puncturing any soft bone tissue of the infant. The design of babyLance delivers incision depths that are optimal for infant heel sticks through a pendulum cutting action which creates a single perfect cut, reducing the pain during incision.
Mr Sun joined MediPurpose under A*STAR's Technology for Enterprise Capability Upgrading (T-UP) scheme, where A*STAR researchers are seconded to Small and Medium Enterprises (SMEs) for up to 2 years to provide them with Research and Development capabilities to help them improve production process or develop products.
The babyLance heel incision device is listed with FDA (Food and Drug Administration) and received the CE (European Conformity) marking for Europe. The market size for baby heel incision devices in USA is about 30 million pieces a year (Source: GHX 2010)
"The global launch of babyLance is a testimony of SIMTech's strong ties with the industry. This collaboration between MediPurpose and SIMTech should inspire Singapore SMEs to create innovative medical devices through product design and technology. Company size is not a barrier to tap the opportunities in the growing global medtech industry," commented Dr Lim Ser Yong, Executive Director of SIMTech.
"We are very excited about this latest addition to our blood collection medical product portfolio," said MediPurpose founder and CEO Patrick Yi. "After successfully entering the U.S. healthcare market, we commissioned SIMTech to conduct a feasibility study of the heel incision device to complement our first product, the SurgiLance(R) safety lancet. SIMTech followed up on that study by seconding Sun to work with our engineers."
The babyLance will be available in two models:
- The babyLance Newborn (BLN), which delivers an incision depth of 1.00 mm.
- The babyLance Preemie (BLP), which delivers an incision depth of 0.85 mm.
In particular, the babyLance heel incision device includes thoughtful innovative features for end-users in providing safety, comfort and ease of use:
- Ease of activation: Reduces trigger activation force, thereby significantly reducing the risk of bruising
- Unique positioning design: Facilitates a stable and accurate placement against the targeted section of the infant's heel while ensuring the procedure can be performed consistently and quickly
- Compliance with regulatory and quality standards: The babyLance cutting blade's swift pendulum action makes an incision that complies with the CLSI LA4-A5 established guidelines
- Cost effectiveness: The babyLance heel incision device incorporates unique design characteristics that allow for the most cost-effective manufacturing process
More information about babyLance - including demonstration videos and free product sample requests - is available at www.medipurpose.com/babylance.
About MediPurpose
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe. Known for its innovation of the SurgiLance(R) Safety Lancet, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor. MediPurpose also offers angel funding, medical product development and medical device consulting for medical device inventors and medical product companies seeking entrance or expansion into the medical device markets. For more information about MediPurpose's medical products, medical distribution channel management services and medical device development services, please visit www.medipurpose.com.
About Singapore Institute of Manufacturing Technology (SIMTech)
The Singapore Institute of Manufacturing Technology (SIMTech) is a research institute of the Science and Engineering Research Council (SERC) of the Agency for Science, Technology and Research (A*STAR). SIMTech develops high value manufacturing technology and human capital to contribute to the competitiveness of the Singapore industry. It collaborates with multinational and local companies in the precision engineering, electronics, semiconductor, medical technology, aerospace, automotive, marine, logistics and other sectors. For more information, please visit: www.SIMTech.a-star.edu.sg.
Contact:
Patrick Yi, Founder and CEO
tel: +1-770-448-9493
e-mail: patrickyi@medipurpose.com
Mark Stoppenbach, Vice President - Blood Collection and Analytics
tel: +1-770-448-9493
e-mail: markstoppenbach@medipurpose.com
Lee Swee Heng
Science and Engineering Institutes
for Singapore Institute of Manufacturing Technology
Tel: +65-6793-8368
Email: leesh@scei.a-star.edu.sg
Topic: New Product
Source: A*STAR
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| A*STAR |
| Dec 6, 2022 14:00 HKT/SGT |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| Sept 30, 2021 16:00 HKT/SGT |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
| July 31, 2020 08:00 HKT/SGT |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| July 24, 2020 17:00 HKT/SGT |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| Oct 22, 2019 04:00 HKT/SGT |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| June 28, 2019 08:00 HKT/SGT |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| Apr 5, 2019 18:00 HKT/SGT |
|
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow |
| Jan 21, 2019 13:00 HKT/SGT |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
| More news >> |
 |
|
|
|
